Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.01.2021 | Case report

Axicabtagene-ciloleucel

Cytokine release syndrome and neurotoxicity: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Jacobson CA, et al. Axicabtagene ciloleucel in the non-trial setting: Outcomes and correlates of response, resistance, and toxicity. Journal of Clinical Oncology 38: 3095-3106, No. 27, 20 Sep 2020. Available from: URL: http://doi.org/10.1200/JCO.19.02103 Jacobson CA, et al. Axicabtagene ciloleucel in the non-trial setting: Outcomes and correlates of response, resistance, and toxicity. Journal of Clinical Oncology 38: 3095-3106, No. 27, 20 Sep 2020. Available from: URL: http://​doi.​org/​10.​1200/​JCO.​19.​02103
Metadaten
Titel
Axicabtagene-ciloleucel
Cytokine release syndrome and neurotoxicity: 2 case reports
Publikationsdatum
01.01.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-87959-y

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Antiretrovirals

Case report

Multiple drugs